Clinical practice guidelines in hypertension: a review

Abstract

The aim of this study is the methodological evaluation of Clinical Practice Guidelines (CPG) in hypertension. This is the first in a series of review articles, analysis, assessment in methodology and content of clinical practice guidelines in Cardiology. Of all clinical practice guidelines, three were selected and the Appraisal of Guidelines for Research and Evaluation (AGREE II) instrument was used to assess each guide. The guidelines obtained the lowest score in the domain of applicability (mean 43.8%); while the highest score was for clarity of presentation (mean 81.5%). The lowest percentage was found in the applicability domain (European guideline) and the highest of all scores was found in two domains: scope and purpose, and clarity of presentation (Canadian guideline). Assessing the quality of the clinical practice guidelines analyzed, the Canadian is one with the best scores obtained by applying the AGREE II instrument, and it is advised to be used without modifications.

Formulation of Polymeric Multicomponent Systems Containing Cardiovascular APIs

“…The developed formulation is intended to improve the drug solubility of the two selected APIs: amlodipine besylate (solubility 1.91099 g/L (water, 32 0 C)) and valsartan (solubility 1.406 mg/L (water, 25 0 C), solubility in methanol and ethanol). The fixed-dose combination (AML:VAL = 1:16 (mg)) was chosen based on Hypertension Clinical Guidelines [8][9][10][11][12]. Two parameters were varied: the concentration of PLGA (17, 34 and 51 mg) and the stirring speed (1200 and 2400 rpm).…”

El SPRINT en la práctica médica: ¿es momento de modificar el manejo de la hipertensión arterial en Latinoamérica?

“…El logro de la PA meta es uno de los temas más discutidos en las GPC de HTA de mayor uso a nivel mundial y latinoamericano 28 , la mayoría de las cuales fueron publicadas antes de los resultados del SPRINT (tabla 1) 29---32 . Respecto a las metas de PA , no existen cambios en las guías previas de la Sociedad Europea 33 ni en la Canadiense 34 , pero sí entre el octavo y séptimo reporte (PA meta: 140/90 mmHg) 35 .…”

Changes in AGREE II Assessment of the Canadian Hypertension Education Program Guidelines

“…We have carefully read the 2016 Canadian Hypertension Education Program (CHEP) Guideline and compared it against the 2015 CHEP guideline, 1 which we had previously assessed as 1 of the best clinical practice guidelines in hypertension. 2 We evaluated the 2016 guidelines with the Appraisal of Guidelines for Research and Evaluation (AGREE) II instrument, and the highest scores were in the domains of scope and purpose and clarity of presentation, with most domains having scores > 70%, similar to the 2015 guidelines. 2 There was no difference in scores between the 2015 and the 2016 guidelines; however, we found differences when assessing the number of recommendations (Table 1).…”

“…2 We evaluated the 2016 guidelines with the Appraisal of Guidelines for Research and Evaluation (AGREE) II instrument, and the highest scores were in the domains of scope and purpose and clarity of presentation, with most domains having scores > 70%, similar to the 2015 guidelines. 2 There was no difference in scores between the 2015 and the 2016 guidelines; however, we found differences when assessing the number of recommendations (Table 1).…”